Under the terms of the agreement, Corgenix has the exclusive rights outside of Japan to further develop the serum amyloid technology, including adapting to research and clinical diagnostic products. This new agreement opens additional avenues of technology and strengthens the collaboration with the Okayama Prefecture (a prefecture is the equivalent of a state) aimed at developing innovative and important diagnostic products in the future.
The agreement with Corgenix is the first one established between the Okayama Prefecture Industrial Promotion Foundation – a government agency promoting research and development among industry, universities and governments – and a US company.
Douglass Simpson, president and CEO of Corgenix, said: “Serum amyloid proteins are stress proteins typically elevated in bacterial and viral infections, and have been shown to be related to cardiovascular disease as well.”